Internalizing RGD (iRGD)-modified liposomal nanoparticles as a universal antigen-delivering platform for remodeling tumors and enhancing T-cell receptor-engineered T cell immunotherapy.
T cell receptor-engineered T cell (TCR-T) therapy holds promise for solid tumors but faces challenges from insufficient and non-uniform antigen presentation and inefficient T-cell tumor delivery. Current strategies that rely on endogenous tumor antigen expression are often limited by transcriptional silencing or downre...